Source: Alpha Cognition.
  • Alpha Cognition (ACOG) has withdrawn its marketed public offering
  • Current market conditions were deemed not conducive to an offering on terms that would be in the best interests of the company’s stockholders
  • Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases
  • Alpha Cognition Inc. (ACOG) is down 10 per cent on the day, trading at C$0.36 per share at 1:45 pm ET

Alpha Cognition (ACOG) has withdrawn its previously-announced marketed public offering.

The company’s management determined that current market conditions are not conducive to an offering on terms that would be in the best interests of the company’s stockholders.

No securities will be sold pursuant to the offering.

Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases.

Alpha Cognition Inc. (ACOG) is down 10 per cent on the day, trading at C$0.36 per share at 1:45 pm ET.

More From The Market Online

Unsung profits: Three money-making penny stocks trading for cheap

To make money in stocks, you need to develop a strong sense for the irrational, a quality often found among cheaply priced penny stocks.

This small-cap gold stock keeps notching high-grade gold in Nevada 

Viva Gold (TSXV:VAU) continues to capitalize on the market thanks to its 100-per-cent-owned Tonopah project in west-central Nevada. 
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.